Organizational Changes at Illumina Aimed at Growth, New Market Entries | GenomeWeb

NEW YORK (GenomeWeb News) – Illumina today announced sweeping changes to its organization in order to maintain growth in its existing markets and to move into new ones.

In a letter to employees, which was filed with the US Securities and Exchange Commission, Illumina President and CEO Jay Flatley laid out the changes, which include the creation of new business units, new roles for existing managers, and the separation of the president's position from Flatley's continued role as CEO.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.